-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the changes in policy and economy, China has begun to promote standardized and individualized prevention and treatment of hemophilia to reduce the disability rate of patients and improve the quality of life of patients
.
In the treatment of hemophilia A, the pharmacokinetics (PK) of patients with coagulation factor Ⅷ (FⅧ) products are significantly different, so PK guides the treatment of hemophilia A to become the dominant treatment
.
With the joint efforts of experts, the first Chinese expert consensus on PK to guide the treatment of hemophilia A in the field of hemophilia was released
.
The release of this consensus is of great significance for guiding the development of individualized treatment clinical practice and promoting the development of hemophilia diagnosis and treatment in China
.
On the occasion of the release of this consensus, Professor Yang Renchi was invited to explain the individualized treatment of hemophilia A in China
.
1.
What is the current status of treatment of hemophilia A in China? How does the Hemophilia Collaborative Group promote the development of hemophilia diagnosis and treatment in China? With the aid of the national economic boom and the unremitting efforts of hemophilia prevention and treatment workers across the country, the overall level of hemophilia A treatment in China has been greatly improved in recent years
.
The specific manifestations are: the prevention and treatment of childhood hemophilia in China has been included in the scope of medical insurance; China has a rich supply of hemophilia A treatment drugs.
In addition to basic products and products from the four approved companies, there are also long-term products that will soon Approved
.
These achievements are worthy of our pride and pride
.
However, compared with the treatment of hemophilia A abroad, there is still a big gap, and continuous efforts are needed
.
With the improvement of medical insurance policies and the abundant supply of coagulation factor products, the delay in diagnosis and treatment of hemophilia A in China has been continuously shortened.
It is believed that in the near future, the level of hemophilia prevention and treatment in the country will be further improved
.
The improvement of the prevention and treatment level of hemophilia in China is inseparable from the joint efforts of experts from the Chinese Hemophilia Cooperation Group
.
The Chinese Hemophilia Collaboration Group was established in 2004, and it has been 17 years since
.
The Chinese Hemophilia Collaborative Group has formulated a series of consensus and guidelines for the diagnosis and treatment of hemophilia.
These consensus and guidelines further standardize the prevention and treatment of hemophilia nationwide
.
It is worth writing that in the past two years, the China Hemophilia Collaborative Group has been cooperating with the China Rare Diseases Alliance to carry out capacity assessment work for the construction of hemophilia centers across the country, with a view to improving the performance of hemophilia centers and medical institutions across the country.
The level of prevention and treatment of hemophilia A has benefited hemophilia patients across the country
.
2.
What is the significance of the release of the first Chinese expert consensus on PK to guide the treatment of hemophilia A in the field of hemophilia treatment? The release of the consensus of Chinese experts on PK guiding the treatment of hemophilia A will further promote the prevention and treatment of hemophilia A in China
.
In the past, whether it was on-demand treatment or preventive treatment, fixed-dose drug treatment was given based on the patient's weight
.
In recent years, scholars at home and abroad have found that patients with hemophilia A have different PK characteristics of FⅧ products at different ages.
Therefore, individuals with hemophilia A and the entire population should not continue to use fixed-dose treatment
.
The release of the consensus of Chinese experts on PK guiding the treatment of hemophilia A can help hemophilia workers develop more appropriate and individualized treatment plans for patients to benefit patients
.
From the perspective of government departments, PK guiding the treatment of hemophilia A can also save medical expenses and reduce the burden of disease
.
3.
In the clinical practice of PK-guided individualized treatment, what difficulties will doctors and patients face? To implement PK-guided individualized treatment, medical staff, whether doctors or nurses, must be familiar with consensus, understand how to use PK to guide the formulation of treatment plans, and then conduct standardized diagnosis and treatment under the guidance of relevant experts
.
For patients, the main difficulty lies in the issue of compliance
.
In the past, if patients received on-demand treatment, they only needed to inject FⅧ drugs when bleeding.
If they received preventive treatment, they would usually be treated twice a week
.
If these patients receive PK-guided individualized treatment, they need to complete multiple blood collections at least within a certain period of time.
Patients need to improve compliance and fully cooperate with medical staff to complete the treatment plan
.
At present, the management tools that use PK to guide the treatment of hemophilia A, such as myPKFiT, can achieve sparse sampling (2-3 times) and accurate prediction.
I believe that improving patient compliance is no longer a difficult point
.
4.
FVIII activity detection is an important link in the construction of hemophilia centers and PK testing.
What are the current areas for improvement in FVIII activity detection? Although the level of prevention and treatment of hemophilia across the country has been greatly improved, during the evaluation and licensing of hemophilia centers carried out by the China Hemophilia Cooperation Group and the Rare Disease Alliance, many medical institutions were found to be unable to carry out FVIII testing and are already carrying out FVIII testing.
Medical institutions also have the problem of non-standard testing
.
In the future we hope to promote the prevention and treatment of hemophilia A PK guidance, the further standardize the detection of FVIII hemophilia A patients
.
I take this opportunity to also call on all hemophilia centers and medical institutions to actively participate in the external quality control of the national coagulation factor (FVIII, FIX) testing, and to supervise and standardize the FVIII testing of these centers
.
Professor Yang Renchi Chief Physician, Doctoral Supervisor, Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology) Thrombosis and Hemostasis Diagnosis and Treatment Center Director, Ministry of Health Tugong Expert, Member of the Steering Committee of the Asia-Pacific Hemophilia Working Group Enjoying the State Council Special Government Allowance Hemostasis and Thrombosis Branch Deputy Director, Chinese Research Hospital Association Rare Disease Branch Executive Director, Thrombosis and Hemostasis Professional Committee Standing Committee Member, Chinese Medical Association Hematology Branch Member, Chinese Pathophysiological Society Experimental Hematology Professional Committee Deputy Group Leader of Vascular Biology Group Rare in China The leader of the Hematology Working Group, the leader of the National Hemophilia Collaboration Group, the editor-in-chief of Haemophila Chinese Edition, the editorial board of Haemophila, the Chinese Journal of Hematology, etc.
, as the first author or corresponding author, published more than 100 SCI-listed papers and successively obtained national scientific and technological progress.
The second prize of the Tianjin Science and Technology Progress Award, the first prize of the Tianjin Science and Technology Progress Award, and the second prize of the Ministry of Education Science and Technology Progress Award VV-MEDMAT-49381 Statement This information is intended to help medical and health professionals better understand the latest developments in the field of related diseases
.
The content of the information published by this site does not mean that it agrees with its description and opinions, but only provides more information
.
If copyright issues are involved, please contact us, and we will deal with it as soon as possible
.
Only for medical and health professionals to understand the information
.
Such information cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding the information, this site and the author shall not bear related responsibilities
.
Poke "read the original text", we make progress together
.
In the treatment of hemophilia A, the pharmacokinetics (PK) of patients with coagulation factor Ⅷ (FⅧ) products are significantly different, so PK guides the treatment of hemophilia A to become the dominant treatment
.
With the joint efforts of experts, the first Chinese expert consensus on PK to guide the treatment of hemophilia A in the field of hemophilia was released
.
The release of this consensus is of great significance for guiding the development of individualized treatment clinical practice and promoting the development of hemophilia diagnosis and treatment in China
.
On the occasion of the release of this consensus, Professor Yang Renchi was invited to explain the individualized treatment of hemophilia A in China
.
1.
What is the current status of treatment of hemophilia A in China? How does the Hemophilia Collaborative Group promote the development of hemophilia diagnosis and treatment in China? With the aid of the national economic boom and the unremitting efforts of hemophilia prevention and treatment workers across the country, the overall level of hemophilia A treatment in China has been greatly improved in recent years
.
The specific manifestations are: the prevention and treatment of childhood hemophilia in China has been included in the scope of medical insurance; China has a rich supply of hemophilia A treatment drugs.
In addition to basic products and products from the four approved companies, there are also long-term products that will soon Approved
.
These achievements are worthy of our pride and pride
.
However, compared with the treatment of hemophilia A abroad, there is still a big gap, and continuous efforts are needed
.
With the improvement of medical insurance policies and the abundant supply of coagulation factor products, the delay in diagnosis and treatment of hemophilia A in China has been continuously shortened.
It is believed that in the near future, the level of hemophilia prevention and treatment in the country will be further improved
.
The improvement of the prevention and treatment level of hemophilia in China is inseparable from the joint efforts of experts from the Chinese Hemophilia Cooperation Group
.
The Chinese Hemophilia Collaboration Group was established in 2004, and it has been 17 years since
.
The Chinese Hemophilia Collaborative Group has formulated a series of consensus and guidelines for the diagnosis and treatment of hemophilia.
These consensus and guidelines further standardize the prevention and treatment of hemophilia nationwide
.
It is worth writing that in the past two years, the China Hemophilia Collaborative Group has been cooperating with the China Rare Diseases Alliance to carry out capacity assessment work for the construction of hemophilia centers across the country, with a view to improving the performance of hemophilia centers and medical institutions across the country.
The level of prevention and treatment of hemophilia A has benefited hemophilia patients across the country
.
2.
What is the significance of the release of the first Chinese expert consensus on PK to guide the treatment of hemophilia A in the field of hemophilia treatment? The release of the consensus of Chinese experts on PK guiding the treatment of hemophilia A will further promote the prevention and treatment of hemophilia A in China
.
In the past, whether it was on-demand treatment or preventive treatment, fixed-dose drug treatment was given based on the patient's weight
.
In recent years, scholars at home and abroad have found that patients with hemophilia A have different PK characteristics of FⅧ products at different ages.
Therefore, individuals with hemophilia A and the entire population should not continue to use fixed-dose treatment
.
The release of the consensus of Chinese experts on PK guiding the treatment of hemophilia A can help hemophilia workers develop more appropriate and individualized treatment plans for patients to benefit patients
.
From the perspective of government departments, PK guiding the treatment of hemophilia A can also save medical expenses and reduce the burden of disease
.
3.
In the clinical practice of PK-guided individualized treatment, what difficulties will doctors and patients face? To implement PK-guided individualized treatment, medical staff, whether doctors or nurses, must be familiar with consensus, understand how to use PK to guide the formulation of treatment plans, and then conduct standardized diagnosis and treatment under the guidance of relevant experts
.
For patients, the main difficulty lies in the issue of compliance
.
In the past, if patients received on-demand treatment, they only needed to inject FⅧ drugs when bleeding.
If they received preventive treatment, they would usually be treated twice a week
.
If these patients receive PK-guided individualized treatment, they need to complete multiple blood collections at least within a certain period of time.
Patients need to improve compliance and fully cooperate with medical staff to complete the treatment plan
.
At present, the management tools that use PK to guide the treatment of hemophilia A, such as myPKFiT, can achieve sparse sampling (2-3 times) and accurate prediction.
I believe that improving patient compliance is no longer a difficult point
.
4.
FVIII activity detection is an important link in the construction of hemophilia centers and PK testing.
What are the current areas for improvement in FVIII activity detection? Although the level of prevention and treatment of hemophilia across the country has been greatly improved, during the evaluation and licensing of hemophilia centers carried out by the China Hemophilia Cooperation Group and the Rare Disease Alliance, many medical institutions were found to be unable to carry out FVIII testing and are already carrying out FVIII testing.
Medical institutions also have the problem of non-standard testing
.
In the future we hope to promote the prevention and treatment of hemophilia A PK guidance, the further standardize the detection of FVIII hemophilia A patients
.
I take this opportunity to also call on all hemophilia centers and medical institutions to actively participate in the external quality control of the national coagulation factor (FVIII, FIX) testing, and to supervise and standardize the FVIII testing of these centers
.
Professor Yang Renchi Chief Physician, Doctoral Supervisor, Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology) Thrombosis and Hemostasis Diagnosis and Treatment Center Director, Ministry of Health Tugong Expert, Member of the Steering Committee of the Asia-Pacific Hemophilia Working Group Enjoying the State Council Special Government Allowance Hemostasis and Thrombosis Branch Deputy Director, Chinese Research Hospital Association Rare Disease Branch Executive Director, Thrombosis and Hemostasis Professional Committee Standing Committee Member, Chinese Medical Association Hematology Branch Member, Chinese Pathophysiological Society Experimental Hematology Professional Committee Deputy Group Leader of Vascular Biology Group Rare in China The leader of the Hematology Working Group, the leader of the National Hemophilia Collaboration Group, the editor-in-chief of Haemophila Chinese Edition, the editorial board of Haemophila, the Chinese Journal of Hematology, etc.
, as the first author or corresponding author, published more than 100 SCI-listed papers and successively obtained national scientific and technological progress.
The second prize of the Tianjin Science and Technology Progress Award, the first prize of the Tianjin Science and Technology Progress Award, and the second prize of the Ministry of Education Science and Technology Progress Award VV-MEDMAT-49381 Statement This information is intended to help medical and health professionals better understand the latest developments in the field of related diseases
.
The content of the information published by this site does not mean that it agrees with its description and opinions, but only provides more information
.
If copyright issues are involved, please contact us, and we will deal with it as soon as possible
.
Only for medical and health professionals to understand the information
.
Such information cannot replace professional medical guidance in any way, nor should it be regarded as diagnosis and treatment advice
.
If such information is used for purposes other than understanding the information, this site and the author shall not bear related responsibilities
.
Poke "read the original text", we make progress together
